{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:07:36Z","timestamp":1792800456218,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,7,13]],"date-time":"2016-07-13T00:00:00Z","timestamp":1468368000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Breakthrough Cancer Research","id":[{"id":"https:\/\/ror.org\/036ntj052","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2536-2","type":"journal-article","created":{"date-parts":[[2016,7,13]],"date-time":"2016-07-13T11:21:49Z","timestamp":1468408909000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Antitumour responses induced by a cell-based Reovirus vaccine in murine lung and melanoma models"],"prefix":"10.1186","volume":"16","author":[{"given":"Ciorsdan A.","family":"Campion","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan","family":"Soden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick F.","family":"Forde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,13]]},"reference":[{"key":"2536_CR1","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nrc2622","volume":"9","author":"DX Nguyen","year":"2009","unstructured":"Nguyen DX, Bos PD, Massaque J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9:274\u201384.","journal-title":"Nat Rev Cancer"},{"key":"2536_CR2","unstructured":"American Cancer Society, Atlanta, Georgia. 2015. www.cancer.org\/cancer\/skincancer\/index . \u00a0(Accessed December 2015)."},{"key":"2536_CR3","unstructured":"World Health Organisation (WHO), Geneva, Switzerland. 2015. Fact sheet no. 297. http:\/\/www.who.int\/mediacentre\/factsheets\/fs297\/en\/ . (Accessed December 2015)."},{"key":"2536_CR4","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.oraloncology.2009.09.002","volume":"45","author":"K Saito","year":"2009","unstructured":"Saito K, Shirasawa H, Isegawa N, Shiiba M, Uzawa K, Tanzawa H. Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses. Oral Oncol. 2009;45:1021\u20137.","journal-title":"Oral Oncol"},{"key":"2536_CR5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/MMBR.45.4.483-501.1981","volume":"45","author":"WK Joklik","year":"1981","unstructured":"Joklik WK. Structure and function of the Reovirus genome. Microbiol Rev. 1981;45:483\u2013501.","journal-title":"Microbiol Rev"},{"key":"2536_CR6","first-page":"187","volume":"45","author":"M Kim","year":"2007","unstructured":"Kim M, Chung YH, Johnston RN. Reovirus and tumour oncolysis. J Microbiol. 2007;45:187\u201392.","journal-title":"J Microbiol"},{"key":"2536_CR7","first-page":"1","volume":"289","author":"P Clarke","year":"2005","unstructured":"Clarke P, Richardson-Burns SM, DeBiasi RL, Tyler KL. Mechanisms of apoptosis during Reovirus infection. Curr Top Microbiol Immunol. 2005;289:1\u201324.","journal-title":"Curr Top Microbiol Immunol"},{"key":"2536_CR8","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1172\/JCI9871","volume":"105","author":"KL Norman","year":"2000","unstructured":"Norman KL, Lee PW. Reovirus as a novel oncolytic agent. J Clin Invest. 2000;105:1035\u20138.","journal-title":"J Clin Invest"},{"key":"2536_CR9","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.clon.2008.04.018","volume":"20","author":"C Comins","year":"2008","unstructured":"Comins C, Heinemann L, Harrington K, Melcher A, De Bono J, Pandha H. Reovirus: Viral Therapy for Cancer \u2018as Nature Intended\u2019. Clin Oncol (R Coll Radiol). 2008;20:548\u201354.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2536_CR10","first-page":"24","volume":"21","author":"D Morris","year":"2002","unstructured":"Morris D, Forsyth PA, Paterson AHG, Fonesca K, DiFrancesco LM, Thompson BG, et al. A phase I clinical trial evaluating intralesional Reolysin\u00ae (Reovirus) in histologically confirmed malignancies. Proc Am Soc Clin Oncol. 2002;21:24. Abstract 92.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2536_CR11","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/sj.mt.6300403","volume":"16","author":"P Forsyth","year":"2008","unstructured":"Forsyth P, Roldan G, George D, Wallace C, Palmer CA, Morris D, et al. A phase I trial of intratumoural administration of Reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther. 2008;16:627\u201332.","journal-title":"Mol Ther"},{"key":"2536_CR12","doi-asserted-by":"publisher","first-page":"7127","DOI":"10.1158\/1078-0432.CCR-08-0524","volume":"14","author":"L Vidal","year":"2008","unstructured":"Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, et al. A Phase I study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer. Clin Cancer Res. 2008;14:7127\u201337.","journal-title":"Clin Cancer Res"},{"key":"2536_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.cytogfr.2010.02.006","volume":"21","author":"KJ Harrington","year":"2010","unstructured":"Harrington KJ, Vile RG, Melcher A, Chester J, Pandha HS. Clinical trials with oncolytic Reovirus: Moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev. 2010;21:91\u20138.","journal-title":"Cytokine Growth Factor Rev"},{"key":"2536_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1040-8428(99)00059-1","volume":"34","author":"AJA Bremers","year":"2000","unstructured":"Bremers AJA, Parmiani G. Immunology and immunotherapy of human cancer: present concepts and clinical developments. Crit Rev Oncol Hematol. 2000;34:1\u201325.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5566","key":"2536_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1071059","volume":"296","author":"P Matzinger","year":"2002","unstructured":"Matzinger P. The danger model: a renewed sense of self. Science. 2002;296(5566):301\u20135.","journal-title":"Science"},{"issue":"5566","key":"2536_CR16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1126\/science.1068883","volume":"296","author":"R Medzhitov","year":"2002","unstructured":"Medzhitov R, Janeway Jr CA. Decoding the patterns of self and nonself by the innate immune system. Science. 2002;296(5566):298\u2013300.","journal-title":"Science"},{"key":"2536_CR17","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/mt.2008.143","volume":"16","author":"TC Liu","year":"2008","unstructured":"Liu TC, Hwang T, Park BH, Bell J, Kirn DH. The targeted oncolytic poxvirus JX-594 demonstrated antitumoural, antivascular and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther. 2008;16:1637\u201342.","journal-title":"Mol Ther"},{"key":"2536_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nm.3089","volume":"19","author":"J Heo","year":"2013","unstructured":"Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, et al. Randomised dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013;19:329\u201336.","journal-title":"Nat Med"},{"key":"2536_CR19","doi-asserted-by":"publisher","first-page":"185ra 163","DOI":"10.1126\/scitranslmed.3005374","volume":"5","author":"MK Kim","year":"2013","unstructured":"Kim MK, Breitbach CJ, Moon A, Heo J, Lee YK, Cho M, et al. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. Sci Transl Med. 2013;5:185ra 163.","journal-title":"Sci Transl Med"},{"key":"2536_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/1479-5876-10-101","volume":"10","author":"R Fan","year":"2012","unstructured":"Fan R, Wang C, Wang Y, Ren P, Gan P, Ji H, et al. Enhanced antitumoural efficacy and immune response following conditionally replicative adenovirus containing constitutive HSF1 delivery to rodent tumours. J Transl Med. 2012;10:101.","journal-title":"J Transl Med"},{"issue":"21","key":"2536_CR21","first-page":"7321","volume":"63","author":"XF Huang","year":"2003","unstructured":"Huang XF, Ren W, Rollins L, Pittman P, Shah M, Shen L, et al. A broadly applicable, personalised heat shock protein-mediated oncolytic tumour vaccine. Cancer Res. 2003;63(21):7321\u20139.","journal-title":"Cancer Res"},{"issue":"3","key":"2536_CR22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4149\/neo_2010_03_207","volume":"57","author":"K Figova","year":"2010","unstructured":"Figova K, Sobotkova E, Duskova M, Ludvikova V, Vonka V, Eckschlager T. In vitro and in vivo effects of Reovirus on HPV16-transformed mice cells. Neoplasma. 2010;57(3):207\u201314.","journal-title":"Neoplasma"},{"key":"2536_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.imlet.2007.11.012","volume":"116","author":"S Gross","year":"2008","unstructured":"Gross S, Walden P. Immunosuppressive mechanisms in human tumours: Why we still cannot cure cancer. Immunol Lett. 2008;116:7\u201314.","journal-title":"Immunol Lett"},{"key":"2536_CR24","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/mt.2009.66","volume":"17","author":"S Ahmed","year":"2009","unstructured":"Ahmed S, Casey G, Sweeney P, Tangney M, O\u2019Sullivan GC. Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Mol Ther. 2009;17:1101\u20138.","journal-title":"Mol Ther"},{"key":"2536_CR25","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/nm.2161","volume":"16","author":"R Jaini","year":"2010","unstructured":"Jaini R, Kesaraju P, Johnson JM, Altuntas CZ, Jane-Wit D, Tuohy VK. An autoimmune-mediated strategy for prophylactic breast cancer vaccination. Nat Med. 2010;16:799\u2013803.","journal-title":"Nat Med"},{"key":"2536_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cytogfr.2010.02.008","volume":"21","author":"F Boeuf Le","year":"2010","unstructured":"Le Boeuf F, Bell JC. United virus: The oncolytic tag-team against cancer! Cytokine Growth Factor Rev. 2010;21:205\u201311.","journal-title":"Cytokine Growth Factor Rev"},{"key":"2536_CR27","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S0022-5347(01)65673-8","volume":"156","author":"SG Krege","year":"1996","unstructured":"Krege SG, Giani G, Meyer R, Otto T, Rubben H. A randomised multicentre trial of adjuvant therapy in superficial bladder cancer: Transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus Bacillus-Calmette-Guerin. J Urol. 1996;156:962\u20136.","journal-title":"J Urol"},{"key":"2536_CR28","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1136\/jmg.2004.027961","volume":"42","author":"AM Woodward","year":"2005","unstructured":"Woodward AM, Davis TA, Silva AG, Kirk JA, Leary JA, kConFab Investigators. Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast\/ovarian cancer phenotype in selected families. J Med Genet. 2005;42:e31.","journal-title":"J Med Genet"},{"key":"2536_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000386035","volume":"13","author":"FM Burnett","year":"1970","unstructured":"Burnett FM. The concept of immunological surveillance. Prog Exp Tumor Res. 1970;13:1\u201327.","journal-title":"Prog Exp Tumor Res"},{"key":"2536_CR30","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1634\/theoncologist.11-4-397","volume":"11","author":"R Horssen van","year":"2006","unstructured":"van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects and clinical utility. Oncologist. 2006;11:397\u2013408.","journal-title":"Oncologist"},{"key":"2536_CR31","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s12026-011-8262-6","volume":"51","author":"T Sato","year":"2011","unstructured":"Sato T, Terai M, Tamura Y, Alexeez V, Mastrangelo MJ, Selvan SR. Interleukin 10 in the tumour microenvironment: a target for anticancer immunotherapy. Immunol Res. 2011;51:170\u201382.","journal-title":"Immunol Res"},{"key":"2536_CR32","unstructured":"Wood, JP. Understanding Immunology. 2nd ed. London, England:\u00a0Pearson\u00a0Prentice Hall; 2006"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2536-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-016-2536-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2536-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2536-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T18:26:36Z","timestamp":1600885596000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2536-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,13]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2536"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2536-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,13]]},"article-number":"462"}}